Business Context and Reporting Period
This Form 8-K filing by Immudyne, Inc. (not Lifemd, Inc.) reports on events occurring on November 26, 2017, and May 20, 2018. The filing details a material definitive agreement and its subsequent amendment regarding the licensing of scar treatment products.
Key Financial Metrics and Agreement Terms
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt). Instead, it outlines specific financial obligations and potential equity dilution tied to the Scarology license agreement:
- License Fee (Original): $100,000 payable in two installments.
- License Fee (Amended): Reduced to $50,000, payable in six monthly installments of $8,333, with an additional $50,000 due by December 1, 2018, if the agreement remains active.
- Royalties: 10% of Net Revenue generated from product sales.
- Performance Milestones: Minimum annual sales of 25,000 units (first year) and 50,000 units (subsequent years) to maintain exclusivity; 10,000 units outside the U.S. to maintain international exclusivity.
- Warrant Triggers:
- If annual Gross Revenue reaches $10,000,000: Scarology may exchange 25% of royalties for a warrant to purchase 500,000 shares at $0.75.
- If annual Gross Revenue reaches $20,000,000: Scarology may exchange an additional 25% of royalties for a warrant to purchase 500,000 shares at $1.50.
Material Changes and Amendments
On May 20, 2018, the parties entered into a First Amendment to the original November 2017 agreement. Key changes include:
- Termination Rights: Immudyne PR gained the right to terminate the agreement at any time with 30 days' written notice.
- Payment Restructuring: The total license fee was reduced from $100,000 to $50,000 initially, with a conditional second $50,000 payment, and the payment schedule was changed to monthly installments.
- Equity Conversion: New provisions were added allowing Scarology to convert royalty rights into stock warrants based on revenue thresholds.
Outlook, Risks, and Contingencies
Management Commentary: The filing is a factual disclosure of contract terms and does not contain forward-looking guidance or management commentary on future performance.
Risks and Contingencies:
- Loss of Exclusivity: Failure to meet annual sales targets (25,000 or 50,000 units) or international sales targets (10,000 units) will result in the license becoming non-exclusive.
- Equity Dilution: Significant revenue generation ($10M or $20M) could trigger the issuance of up to 1,000,000 shares of common stock to Scarology.
- Termination: The agreement can be terminated by either party for insolvency, bankruptcy, material breach, or by Scarology with 90 days' notice (or by Immudyne with 30 days' notice per the amendment).
Investor Verification Checklist
- Verify the current status of the $50,000 conditional license fee payment due by December 1, 2018.
- Confirm whether annual sales targets (25,000/50,000 units) have been met to maintain exclusivity.
- Assess the potential dilution impact if revenue thresholds of $10M or $20M are reached, triggering the issuance of 1,000,000 shares.
- Review the full text of Exhibit 10.1 and 10.2 for definitions of "Net Revenue" and "Gross Revenue" to understand royalty and warrant calculations.